115
Views
43
CrossRef citations to date
0
Altmetric
Original Article

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

, &
Pages 657-664 | Accepted 11 Mar 2005, Published online: 01 Apr 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Takashi Shigematsu, Yuri Nakashima, Masaki Ohya, Koichi Tatsuta, Daisuke Koreeda, Wataru Yoshimoto, Shintaro Yamanaka, Toshifumi Sakaguchi, Yoshiyuki Hanba, Toru Mima & Shigeo Negi. (2012) The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients. International Journal of Nephrology and Renovascular Disease 5, pages 81-89.
Read now
Amy Barton Pai, Todd A Conner & Charles R McQuade. (2009) Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opinion on Drug Metabolism & Toxicology 5:1, pages 71-81.
Read now

Articles from other publishers (40)

A. Vardhan & A. J. Hutchison. 2020. Nolph and Gokal's Textbook of Peritoneal Dialysis. Nolph and Gokal's Textbook of Peritoneal Dialysis 1 37 .
A. Vardhan & A. J. Hutchison. 2023. Nolph and Gokal's Textbook of Peritoneal Dialysis. Nolph and Gokal's Textbook of Peritoneal Dialysis 537 573 .
Jan Aaseth & Balazs Berlinger. 2022. Handbook on the Toxicology of Metals. Handbook on the Toxicology of Metals 419 425 .
Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio, Grahame J Elder & Giovanni FM Strippoli. (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database of Systematic Reviews 2018:8.
Crossref
C. Estruch Bosch, M.P. Copley, T. Eralp, E. Bilbé, J.W. Thybaut, G.B. Marin & P. Collier. (2017) Tailoring the physical and catalytic properties of lanthanum oxycarbonate nanoparticles. Applied Catalysis A: General 536, pages 104-112.
Crossref
Ahmed M. Shaman & Stefan R. Kowalski. (2016) Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharmaceutical Journal 24:4, pages 494-505.
Crossref
Richard P. Wedeen, Balazs Berlinger & Jan Aaseth. 2015. Handbook on the Toxicology of Metals. Handbook on the Toxicology of Metals 903 909 .
Steven Wang, Emmanuel A. Anum, Karthik Ramakrishnan, Thomas Alfieri, Peter Braunhofer & Britt Newsome. (2014) Reasons for Phosphate Binder Discontinuation Vary by Binder Type. Journal of Renal Nutrition 24:2, pages 105-109.
Crossref
Emilio González-Parra, Carolina Gracia-Iguacel, Jesús Egido & Alberto Ortiz. 2013. Clinical Nutrition. Clinical Nutrition 141 153 .
E. A. NUNAMAKER & J. G. SHERMAN. (2011) Oral administration of lanthanum dioxycarbonate does not alter bone morphology of normal cats. Journal of Veterinary Pharmacology and Therapeutics 35:2, pages 193-197.
Crossref
João M. Frazão & Teresa Adragão. (2012) Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects. Nephron Clinical Practice 120:2, pages c108-c119.
Crossref
Emilio González-Parra, Carolina Gracia-Iguacel, Jesús Egido & Alberto Ortiz. (2012) Phosphorus and Nutrition in Chronic Kidney Disease. International Journal of Nephrology 2012, pages 1-5.
Crossref
L. Darryl Quarles. 2012. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney 2240 2257 .
Haesuk Park, Karen L. Rascati, Michael S. Keith, Paul Hodgkins, Michael Smyth, David Goldsmith & Ron Akehurst. (2011) Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value in Health 14:8, pages 1002-1009.
Crossref
Alexandra Gramowski, Konstantin Jügelt, Olaf H.-U. Schröder, Dieter G. Weiss & Steffen Mitzner. (2011) Acute Functional Neurotoxicity of Lanthanum(III) in Primary Cortical Networks. Toxicological Sciences 120:1, pages 173-183.
Crossref
Donald A. Molony & Brett W. Stephens. (2011) Derangements in Phosphate Metabolism in Chronic Kidney Diseases/Endstage Renal Disease: Therapeutic Considerations. Advances in Chronic Kidney Disease 18:2, pages 120-131.
Crossref
Takashi Shigematsu. (2010) Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clinical and Experimental Nephrology 14:6, pages 589-597.
Crossref
N. Carrillo-Lopez, J. L. Fernandez-Martin, D. Alvarez-Hernandez, I. Gonzalez-Suarez, P. Castro-Santos, P. Roman-Garcia, J. M. Lopez-Novoa & J. B. Cannata-Andia. (2010) Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrology Dialysis Transplantation 25:9, pages 2930-2937.
Crossref
Marcello Tonelli, Neesh Pannu & Braden Manns. (2010) Oral Phosphate Binders in Patients with Kidney Failure. New England Journal of Medicine 362:14, pages 1312-1324.
Crossref
Takashi Shigematsu. (2010) One Year Efficacy and Safety of Lanthanum Carbonate for Hyperphosphatemia in Japanese Chronic Kidney Disease Patients Undergoing Hemodialysis. Therapeutic Apheresis and Dialysis 14:1, pages 12-19.
Crossref
M. Clotilde, C. Francois & F. Bernadette. (2009) Reply. Nephrology Dialysis Transplantation 24:12, pages 3899-3900.
Crossref
Monique P. Curran & Dean M. Robinson. (2009) Lanthanum Carbonate. Drugs 69:16, pages 2329-2349.
Crossref
STACEY O'SHEA & DAVID W JOHNSON. (2009) Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient-level outcomes?. Nephrology 14:4, pages 416-427.
Crossref
An R.J. Bervoets, Geert J. Behets, Dominick Schryvers, Frank Roels, Zhang Yang, Steven C. Verberckmoes, Stephen J.P. Damment, Simonne Dauwe, Valentine K. Mubiana, Ronny Blust, Marc E. De Broe & Patrick C. D'Haese. (2009) Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney International 75:4, pages 389-398.
Crossref
A. Vardhan & A. J. Hutchison. 2009. Nolph and Gokal’s Textbook of Peritoneal Dialysis. Nolph and Gokal’s Textbook of Peritoneal Dialysis 649 677 .
H. Kawanishi, M. Ishida, M. Ishizaki, Y. Takuma, H. Tamura, S. Kobayashi, T. Tamura, H. Ohashi, M. Hiramatsu, J. Minakuchi, H. Hirakata & T. Shigematsu. (2008) Lanthanum Carbonate Treatment of Patients with Hyperphosphatemia Undergoing CAPD. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 28:6, pages 673-675.
Crossref
N. K. Prasad, K. Rathinasamy, D. Panda & D. Bahadur. (2008) TC-tuned biocompatible suspension of La0.73Sr0.27MnO3 for magnetic hyperthermia. Journal of Biomedical Materials Research Part B: Applied Biomaterials 85B:2, pages 409-416.
Crossref
Pouneh Nouri & Francisco Llach. 2008. Therapy in Nephrology & Hypertension. Therapy in Nephrology & Hypertension 412 425 .
William G. Goodman. 2008. Principles of Bone Biology. Principles of Bone Biology 1479 1510 .
S. Bandini & M. Lombardi. (2018) Trattamento della iperfosforemia del paziente uremico: I nuovi chelanti. Giornale di Tecniche Nefrologiche e Dialitiche 19:3-4, pages 13-20.
Crossref
Declan de Freitas, Rosemary L. Donne & Alastair J. Hutchison. (2007) PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Lanthanum Carbonate-A First Line Phosphate Binder?. Seminars in Dialysis 20:4, pages 325-328.
Crossref
Tilman B. Drüeke. (2007) PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Lanthanum Carbonate as a First-Line Phosphate Binder: The “Cons”. Seminars in Dialysis 20:4, pages 329-332.
Crossref
M. Cozzolino & D. Brancaccio. (2018) Hyperphosphatemia in Dialysis Patients: The Therapeutic Role of Lanthanum Carbonate. The International Journal of Artificial Organs 30:4, pages 293-300.
Crossref
Krishna R. Polu & Ajay K. Singh. 2007. Calcium and Phosphate Metabolism Management in Chronic Renal Disease. Calcium and Phosphate Metabolism Management in Chronic Renal Disease 29 70 .
Antonio BELLASI, Laura KOOIENGA & Geoffrey A. BLOCK. (2006) Phosphate binders: New products and challenges. Hemodialysis International 10:3, pages 225-234.
Crossref
Pauline Branley. (2006) Use of phosphate binders in chronic kidney disease. Nephrology 11, pages S245-S262.
Crossref
Christine M Cheng. (2016) Lanthanum Carbonate Treatment of Hyperphosphatemia in End-Stage Renal Disease. Journal of Pharmacy Technology 22:2, pages 99-104.
Crossref
Melanie S Joy, Abhijit Kshirsagar, Corina Candiani, Tyson Brooks & Joanna Q Hudson. (2016) Lanthanum Carbonate. Annals of Pharmacotherapy 40:2, pages 234-240.
Crossref
Simon P. Fricker. (2006) The therapeutic application of lanthanides. Chemical Society Reviews 35:6, pages 524.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:12, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.